Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares Repurchased
Ratios

Core Laboratories (CLB) EBIAT (2022 - 2026)

Core Laboratories filings provide 5 years of EBIAT readings, the most recent being -$753000.0 for Q1 2026.

  • On a quarterly basis, EBIAT fell 388.96% to -$753000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $29.1 million, a 3.48% increase, with the full-year FY2025 number at $29.7 million, down 7.73% from a year prior.
  • EBIAT hit -$753000.0 in Q1 2026 for Core Laboratories, down from $4.9 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $22.9 million in Q2 2023 to a low of -$753000.0 in Q1 2026.
  • Median EBIAT over the past 5 years was $7.3 million (2022), compared with a mean of $7.4 million.
  • Biggest five-year swings in EBIAT: surged 239.65% in 2024 and later plummeted 388.96% in 2026.
  • Core Laboratories' EBIAT stood at $6.5 million in 2022, then plummeted by 66.09% to $2.2 million in 2023, then surged by 239.65% to $7.5 million in 2024, then crashed by 33.75% to $4.9 million in 2025, then crashed by 115.22% to -$753000.0 in 2026.
  • The last three reported values for EBIAT were -$753000.0 (Q1 2026), $4.9 million (Q4 2025), and $14.2 million (Q3 2025) per Business Quant data.